Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis

REFERENCES

• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Parchand S, Tandan M, Gupta V, et al. Intermediate uveitis in Indian population. J Ophthalmic Inflamm Infect. 2011;1:65–70.
   PubMedGoogle Scholar
• de Boer J, Berendschot TT, van der Does P, et al. Long-term follow-up of intermediate uveitis in children. Am J Ophthalmol. 2006;141:616–621.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I. Pediatric uveitis. J Ophthalmic Vis Res. 2011;6:259–269.
   PubMedGoogle Scholar
• Foster C, Vitale A. Diagnosis and Treatment of Uveitis. Philadelphia: WB Saunders; 2002.
   Google Scholar
• Paroli MP, Spinucci G, Monte R, et al. Intermediate uveitis in a pediatric Italian population. Ocul Immunol Inflamm. 2011;19:321–326.
   PubMed Web of Science ®Google Scholar
• Donaldson MJ, Pulido JS, Herman DC, et al. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol. 2007;144:812–817.
   PubMed Web of Science ®Google Scholar
• Arellanes-García L, Navarro-López P, Concha-Del Río LE, et al. Idiopathic intermediate uveitis in childhood. Int Ophthalmol Clin. 2008;48:61–74.
   PubMedGoogle Scholar
• Jain R, Ferrante P, Reddy GT, et al. Clinical features and visual outcome of intermediate uveitis in children. Clin Experiment Ophthalmol. 2005;33:22–25.
   PubMed Web of Science ®Google Scholar
• Vidovic-Valentincic N, Kraut A, Hawlina M, et al. Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol. 2009;93:477–480.
   PubMed Web of Science ®Google Scholar
• Maris K, Van Calster J, Wouters C, et al. Clinical symptoms and complications of pars planitis in childhood. Bull Soc Belge Ophtalmol. 2005:29–33.
   Google Scholar
• Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116:1544–1551.
   PubMed Web of Science ®Google Scholar
• Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clin Experiment Ophthalmol. 2001;29:81–84.
   PubMed Web of Science ®Google Scholar
• Nagpal A, Leigh JF, Acharya NR. Epidemiology of uveitis in children. Int Ophthalmol Clin. 2008;48:1–7.
   PubMedGoogle Scholar
• Cunningham ET. Uveitis in children. Ocul Immunol Inflamm. 2000;8:251–261.
   PubMed Web of Science ®Google Scholar
• Aaberg TM. The enigma of pars planitis. Am J Ophthalmol. 1987;103:828–830.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
   PubMed Web of Science ®Google Scholar
• Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis. F1000Prime Rep. 2014;6:41.
   PubMedGoogle Scholar
• Simonini G1, Cantarini L, Bresci C, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev. 2010;9:674–683.
   PubMed Web of Science ®Google Scholar
• Schatz CS, Uzel JL, Leininger L, et al. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis. J Pediatr Ophthalmol Strabismus. 2007;44:28–34.
   PubMed Web of Science ®Google Scholar
• Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308–314.
   PubMed Web of Science ®Google Scholar
• Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25:427–435.
   PubMed Web of Science ®Google Scholar
• Menezo V, Lau C, Comer M, et al. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Experiment Ophthalmol. 2005;33:16–21.
   PubMed Web of Science ®Google Scholar
• Rabinovich CE. Use of tumor necrosis factor inhibitors in uveitis. Curr Opin Rheumatol. 2007;19:482–486.
   PubMed Web of Science ®Google Scholar
• Farvardin M, Afarid M, Mehryar M, et al. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30:1530–1535.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121:1863–1870.
   Google Scholar
• Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-alpha inhibitors. J Rheumatol. 2013;40:1394–1403.
   PubMed Web of Science ®Google Scholar
• Romero R, Peralta J, Sendagorta E, et al. Pars planitis in children: epidemiologic, clinical, and therapeutic characteristics. J Pediatr Ophthalmol Strabismus. 2007;44:288–293.
   PubMed Web of Science ®Google Scholar
• Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol. 2005;89:806–808.
   PubMed Web of Science ®Google Scholar
• Kaplan-Messas A, Barkana Y, Avni I, et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11:131–139.
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–1139.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015;74:1037–1044.
   PubMed Web of Science ®Google Scholar
• Baranauskaite A, Raffayová H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541–548.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Wagner C, Marini JC, et al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J. 2010;8:24.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914–1915.
   Google Scholar
• Nikkhah H, Ramezani A, Ahmadieh H, et al. Childhood pars planitis; clinical features and outcomes. J Ophthalmic Vis Res. 2011;6:249–254.
   PubMedGoogle Scholar
• Kalinina Ayuso V, ten Cate HA, van den Does P, et al. Young age as a risk factor for complicated course and visual outcome in intermediate uveitis in children. Br J Ophthalmol. 2011;95:646–651.
   PubMed Web of Science ®Google Scholar